Related Experiment Video
Updated: Jun 26, 2026
07:36
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
Published on: March 14, 2019
[Biphasic insulin aspart (NovoMix 50)]
1Université de Liège, Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU de Liège, Belgique. regis.radermecker@ulg.ac.be
Revue Medicale De Liege
|December 31, 2008
Summary
NovoMix 50, a biphasic insulin aspart, offers improved postprandial hyperglycemia control in type 2 diabetes management. This insulin preparation provides greater flexibility for physicians in optimizing glycemic control.
Area of Science:
- Pharmacology
- Endocrinology
Context:
- Premixed insulin preparations are vital in managing type 2 diabetes.
- NovoMix 50 represents an advancement in insulin therapy, offering a specific ratio of insulin aspart analogues.
Purpose:
- To introduce NovoMix 50, a new biphasic insulin aspart formulation.
- To highlight its advantages over existing preparations like NovoMix 30, particularly in controlling postprandial hyperglycemia.
Summary:
- NovoMix 50 contains 50% ultra-short-acting insulin aspart and 50% protaminated insulin aspart.
- It provides enhanced control of postprandial hyperglycemia compared to NovoMix 30 due to a higher proportion of rapid-acting insulin.
- NovoMix 70 is also mentioned as an upcoming product, expanding treatment options.
Impact:
- Offers greater flexibility in insulin regimens for type 2 diabetes patients.
- Facilitates better management of prandial and basal glycaemia while minimizing hypoglycemia risk.
- Supports individualized treatment strategies through varied insulin mixture options.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...